Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.9000 (-2.82%) ($6.8100 - $7.1100) on Wed. Apr. 3, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.04% (three month average) | RSI | 26 | Latest Price | $6.9000(-2.82%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.8% a day on average for past five trading days. | Weekly Trend | ADMS declines -5.2% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XOP(13%) OIH(12%) XBI(10%) EWI(9%) ONLN(9%) | Factors Impacting ADMS price | ADMS will decline at least -2.52% in a week (0% probabilities). UUP(-10%) BNDX(-10%) GLD(-8%) GDX(-8%) GDXJ(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.52% (StdDev 5.04%) | Hourly BBV | 0 () | Intraday Trend | -2.8% | | | |
|
1 - 5 Day Possible Target | $-1.16(-116.81%) | Resistance Level | $7.54 | 5 Day Moving Average | $7.11(-2.95%) | 10 Day Moving Average | $7.3(-5.48%) | 20 Day Moving Average | $7.54(-8.49%) | To recent high | -43.2% | To recent low | 0% | Market Cap | $195m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |